{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:00:26Z","timestamp":1780459226903,"version":"3.54.1"},"reference-count":56,"publisher":"American Association for Cancer Research (AACR)","issue":"22","funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["CA164122"],"award-info":[{"award-number":["CA164122"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["CA054174"],"award-info":[{"award-number":["CA054174"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["CA205965"],"award-info":[{"award-number":["CA205965"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"NCATS","doi-asserted-by":"publisher","award":["TL1 TR001119"],"award-info":[{"award-number":["TL1 TR001119"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["CA205568"],"award-info":[{"award-number":["CA205568"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"CPRIT","doi-asserted-by":"publisher","award":["RP170345"],"award-info":[{"award-number":["RP170345"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>The IL2 receptor (IL2R) is an attractive cancer immunotherapy target that controls immunosuppressive T regulatory cells (Treg) and antitumor T cells. Here we used IL2R\u03b2-selective IL2\/anti-IL2 complexes (IL2c) to stimulate effector T cells preferentially in the orthotopic mouse ID8agg ovarian cancer model. Despite strong tumor rejection, IL2c unexpectedly lowered the tumor microenvironmental CD8+\/Treg ratio. IL2c reduced tumor microenvironmental Treg suppression and induced a fragile Treg phenotype, helping explain improved efficacy despite numerically increased Tregs without affecting Treg in draining lymph nodes. IL2c also reduced Treg-mediated, high-affinity IL2R signaling needed for optimal Treg functions, a likely mechanism for reduced Treg suppression. Effector T-cell IL2R signaling was simultaneously improved, suggesting that IL2c inhibits Treg functions without hindering effector T cells, a limitation of most Treg depletion agents. Anti-PD-L1 antibody did not treat ID8agg, but adding IL2c generated complete tumor regressions and protective immune memory not achieved by either monotherapy. Similar anti-PD-L1 augmentation of IL2c and degradation of Treg functions were seen in subcutaneous B16 melanoma. Thus, IL2c is a multifunctional immunotherapy agent that stimulates immunity, reduces immunosuppression in a site-specific manner, and combines with other immunotherapies to treat distinct tumors in distinct anatomic compartments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>These findings present CD122-targeted IL2 complexes as an advancement in cancer immunotherapy, as they reduce Treg immunosuppression, improve anticancer immunity, and boost PD-L1 immune checkpoint blockade efficacy in distinct tumors and anatomic locations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-20-0002","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T14:40:10Z","timestamp":1600440010000},"page":"5063-5075","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade"],"prefix":"10.1158","volume":"80","author":[{"given":"Justin M.","family":"Drerup","sequence":"first","affiliation":[{"name":"1Department of Cell Systems and Anatomy, The Graduate School of Biomedical Sciences, University of Texas Health San Antonio, Texas."},{"name":"2Department of Medicine, University of Texas Health San Antonio, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilun","family":"Deng","sequence":"additional","affiliation":[{"name":"2Department of Medicine, University of Texas Health San Antonio, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Lakshmi","family":"Pandeswara","sequence":"additional","affiliation":[{"name":"2Department of Medicine, University of Texas Health San Antonio, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro S.","family":"Padr\u00f3n","sequence":"additional","affiliation":[{"name":"2Department of Medicine, University of Texas Health San Antonio, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9562-5809","authenticated-orcid":false,"given":"Ryan M.","family":"Reyes","sequence":"additional","affiliation":[{"name":"3Department of Microbiology, Immunology and Molecular Genetics, The Graduate School of Biomedical Sciences, University of Texas Health San Antonio, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Zhang","sequence":"additional","affiliation":[{"name":"4Sun Yat-sen University, Guangzhou, Guangdong, P.R.China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Mendez","sequence":"additional","affiliation":[{"name":"2Department of Medicine, University of Texas Health San Antonio, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijie","family":"Liu","sequence":"additional","affiliation":[{"name":"2Department of Medicine, University of Texas Health San Antonio, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Clark","sequence":"additional","affiliation":[{"name":"2Department of Medicine, University of Texas Health San Antonio, Texas."},{"name":"3Department of Microbiology, Immunology and Molecular Genetics, The Graduate School of Biomedical Sciences, University of Texas Health San Antonio, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanjiao","family":"Chen","sequence":"additional","affiliation":[{"name":"5Xiangya Medical School, Changsha, Hunan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 R.","family":"Conejo-Garcia","sequence":"additional","affiliation":[{"name":"6Department of Immunology, Moffitt Cancer Center, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Hurez","sequence":"additional","affiliation":[{"name":"2Department of Medicine, University of Texas Health San Antonio, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1003-2658","authenticated-orcid":false,"given":"Harshita","family":"Gupta","sequence":"additional","affiliation":[{"name":"2Department of Medicine, University of Texas Health San Antonio, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6962-9411","authenticated-orcid":false,"given":"Tyler J.","family":"Curiel","sequence":"additional","affiliation":[{"name":"2Department of Medicine, University of Texas Health San Antonio, Texas."},{"name":"3Department of Microbiology, Immunology and Molecular Genetics, The Graduate School of Biomedical Sciences, University of Texas Health San Antonio, Texas."},{"name":"7Mays Family Cancer Center, University of Texas Health San Antonio, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2020,11,13]]},"reference":[{"key":"2022061706332093100_bib1","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/nm.4200","article-title":"Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses","volume":"22","author":"Moynihan","year":"2016","journal-title":"Nat Med"},{"key":"2022061706332093100_bib2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nri1806","article-title":"Regulatory T cells, tumour immunity and immunotherapy","volume":"6","author":"Zou","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"2022061706332093100_bib3","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI31202","article-title":"Tregs and rethinking cancer immunotherapy","volume":"117","author":"Curiel","year":"2007","journal-title":"J Clin Invest"},{"key":"2022061706332093100_bib4","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat Med"},{"key":"2022061706332093100_bib5","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/S1470-2045(11)70155-3","article-title":"Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?","volume":"13","author":"Jacobs","year":"2012","journal-title":"Lancet Oncol"},{"key":"2022061706332093100_bib6","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/ni1263","article-title":"A function for interleukin 2 in Foxp3-expressing regulatory T cells","volume":"6","author":"Fontenot","year":"2005","journal-title":"Nat Immunol"},{"key":"2022061706332093100_bib7","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/ni.3540","article-title":"An essential role for the IL-2 receptor in Treg cell function","volume":"17","author":"Chinen","year":"2016","journal-title":"Nat Immunol"},{"key":"2022061706332093100_bib8","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4049\/jimmunol.178.1.280","article-title":"IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells","volume":"178","author":"Burchill","year":"2007","journal-title":"J Immunol"},{"key":"2022061706332093100_bib9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1084\/jem.20131142","article-title":"CCR7 provides localized access to IL-2 and defines homeostatically distinct regulatory T cell subsets","volume":"211","author":"Smigiel","year":"2014","journal-title":"J Exp Med"},{"key":"2022061706332093100_bib10","doi-asserted-by":"crossref","first-page":"311ra170","DOI":"10.1126\/scitranslmed.aac8155","article-title":"IL-2R\u03b1 mediates temporal regulation of IL-2 signaling and enhances immunotherapy","volume":"7","author":"Su","year":"2015","journal-title":"Sci Transl Med"},{"key":"2022061706332093100_bib11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev.immunol.26.021607.090357","article-title":"The biology of interleukin-2","volume":"26","author":"Malek","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"2022061706332093100_bib12","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/369330a0","article-title":"Heterodimerization of the IL-2 receptor beta- and gamma-chain cytoplasmic domains is required for signalling","volume":"369","author":"Nakamura","year":"1994","journal-title":"Nature"},{"key":"2022061706332093100_bib13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0092-8674(93)80067-O","article-title":"Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene","volume":"75","author":"Sadlack","year":"1993","journal-title":"Cell"},{"key":"2022061706332093100_bib14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/1074-7613(95)90180-9","article-title":"Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment","volume":"3","author":"Willerford","year":"1995","journal-title":"Immunity"},{"key":"2022061706332093100_bib15","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1126\/science.7770771","article-title":"Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta","volume":"268","author":"Suzuki","year":"1995","journal-title":"Science"},{"key":"2022061706332093100_bib16","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J Immunol"},{"key":"2022061706332093100_bib17","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/eji.200939613","article-title":"In vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcgammaRIII+ phagocytes","volume":"40","author":"Setiady","year":"2010","journal-title":"Eur J Immunol"},{"key":"2022061706332093100_bib18","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1126\/science.1122927","article-title":"Selective stimulation of T cell subsets with antibody-cytokine immune complexes","volume":"311","author":"Boyman","year":"2006","journal-title":"Science"},{"key":"2022061706332093100_bib19","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1073\/pnas.0909384107","article-title":"IL-2\/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25","volume":"107","author":"Letourneau","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706332093100_bib20","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.it.2015.10.003","article-title":"Interleukin-2: biology, design and application","volume":"36","author":"Arenas-Ramirez","year":"2015","journal-title":"Trends Immunol"},{"key":"2022061706332093100_bib21","doi-asserted-by":"crossref","first-page":"367ra166","DOI":"10.1126\/scitranslmed.aag3187","article-title":"Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2","volume":"8","author":"Arenas-Ramirez","year":"2016","journal-title":"Sci Transl Med"},{"key":"2022061706332093100_bib22","doi-asserted-by":"crossref","first-page":"11906","DOI":"10.1073\/pnas.1002569107","article-title":"Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells","volume":"107","author":"Krieg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706332093100_bib23","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"2022061706332093100_bib24","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"2022061706332093100_bib25","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"2022061706332093100_bib26","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1084\/jem.20161462","article-title":"What does PD-L1 positive or negative mean?","volume":"213","author":"Ribas","year":"2016","journal-title":"J Exp Med"},{"key":"2022061706332093100_bib27","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1158\/0008-5472.CAN-16-0258","article-title":"Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma","volume":"76","author":"Clark","year":"2016","journal-title":"Cancer Res"},{"key":"2022061706332093100_bib28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40425-015-0102-0","article-title":"The dark side of ID8-Luc2: pitfalls for luciferase tagged murine models for ovarian cancer","volume":"3","author":"Baert","year":"2015","journal-title":"J Immunother Cancer"},{"key":"2022061706332093100_bib29","doi-asserted-by":"crossref","first-page":"14649","DOI":"10.1038\/ncomms14649","article-title":"Suppressive IL-17A+Foxp3+ and ex-Th17 IL-17AnegFoxp3+ Treg cells are a source of tumour-associated Treg cells","volume":"8","author":"Downs-Canner","year":"2017","journal-title":"Nat Commun"},{"key":"2022061706332093100_bib30","doi-asserted-by":"crossref","first-page":"e80063","DOI":"10.1371\/journal.pone.0080063","article-title":"The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer","volume":"8","author":"Preston","year":"2013","journal-title":"PLoS One"},{"key":"2022061706332093100_bib31","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706332093100_bib32","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.immuni.2007.08.014","article-title":"Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance","volume":"27","author":"Cao","year":"2007","journal-title":"Immunity"},{"key":"2022061706332093100_bib33","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.immuni.2004.09.002","article-title":"Human T regulatory cells can use the perforin pathway to cause autologous target cell death","volume":"21","author":"Grossman","year":"2004","journal-title":"Immunity"},{"key":"2022061706332093100_bib34","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"2022061706332093100_bib35","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1002\/ijc.25902","article-title":"CD103 is a hallmark of tumor-infiltrating regulatory T cells","volume":"129","author":"Anz","year":"2011","journal-title":"Int J Cancer"},{"key":"2022061706332093100_bib36","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/cmi.2016.30","article-title":"Human CD39(hi) regulatory T cells present stronger stability and function under inflammatory conditions","volume":"14","author":"Gu","year":"2017","journal-title":"Cell Mol Immunol"},{"key":"2022061706332093100_bib37","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.cell.2017.05.005","article-title":"Interferon-gamma drives Treg fragility to promote anti-tumor immunity","volume":"169","author":"Overacre-Delgoffe","year":"2017","journal-title":"Cell"},{"key":"2022061706332093100_bib38","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/nature05479","article-title":"Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression","volume":"445","author":"Wan","year":"2007","journal-title":"Nature"},{"key":"2022061706332093100_bib39","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.immuni.2015.04.015","article-title":"Antibodies to interleukin-2 elicit selective T cell subset potentiation through distinct conformational mechanisms","volume":"42","author":"Spangler","year":"2015","journal-title":"Immunity"},{"key":"2022061706332093100_bib40","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat Immunol"},{"key":"2022061706332093100_bib41","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1073\/pnas.1705327114","article-title":"Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients","volume":"114","author":"Kamphorst","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706332093100_bib42","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12894-016-0121-2","article-title":"Effects of stimulating interleukin -2\/anti- interleukin -2 antibody complexes on renal cell carcinoma","volume":"16","author":"Han","year":"2016","journal-title":"BMC Urol"},{"key":"2022061706332093100_bib43","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11864-014-0317-1","article-title":"Immunotherapy for ovarian cancer","volume":"16","author":"Drerup","year":"2015","journal-title":"Curr Treat Options Oncol"},{"key":"2022061706332093100_bib44","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"2022061706332093100_bib45","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N Engl J Med"},{"key":"2022061706332093100_bib46","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J Immunol"},{"key":"2022061706332093100_bib47","doi-asserted-by":"crossref","first-page":"7487","DOI":"10.1158\/0008-5472.CAN-07-0565","article-title":"Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma","volume":"67","author":"Wei","year":"2007","journal-title":"Cancer Res"},{"key":"2022061706332093100_bib48","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.immuni.2009.10.001","article-title":"Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection","volume":"31","author":"Oldenhove","year":"2009","journal-title":"Immunity"},{"key":"2022061706332093100_bib49","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"2022061706332093100_bib50","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","article-title":"Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer","volume":"34","author":"Massard","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022061706332093100_bib51","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/acel.12380","article-title":"Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice","volume":"14","author":"Hurez","year":"2015","journal-title":"Aging Cell"},{"key":"2022061706332093100_bib52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.coi.2015.12.009","article-title":"T(reg) stability: to be or not to be","volume":"39","author":"Overacre","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"2022061706332093100_bib53","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1078-0432.CCR-15-1631","article-title":"NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models","volume":"22","author":"Charych","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2022061706332093100_bib54","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.immuni.2015.04.018","article-title":"Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps","volume":"42","author":"Mitra","year":"2015","journal-title":"Immunity"},{"key":"2022061706332093100_bib55","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10975","article-title":"Exploiting a natural conformational switch to engineer an interleukin-2 \u2018superkine\u2019","volume":"484","author":"Levin","year":"2012","journal-title":"Nature"},{"key":"2022061706332093100_bib56","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.2623","article-title":"Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab","volume":"37","author":"Hurwitz","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/80\/22\/5063\/2799102\/5063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/80\/22\/5063\/2799102\/5063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T11:18:33Z","timestamp":1696677513000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/80\/22\/5063\/645898\/CD122-Selective-IL2-Complexes-Reduce"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,13]]},"references-count":56,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2020,11,13]]},"published-print":{"date-parts":[[2020,11,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-20-0002","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6512275.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6512275","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22426258","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22426258.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,13]]}}}